Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19
Assad,
Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19,
, H., Current Issues in Pharmacy and Medical Sciences, doi:10.2478/cipms-2022-0020
Retrospective 346 hospitalized patients in Iraq, showing lower mortality with HCQ in unadjusted results. HCQ results are only provided within the 93% of patients treated with enoxaparin.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details;
confounding by time possible, propensity to use HCQ changed significantly during the study period.
risk of death, 59.7% lower, RR 0.40, p = 0.002, treatment 9 of 72 (12.5%), control 68 of 219 (31.1%), NNT 5.4, enoxaparin+HCQ vs. enoxaparin.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Assad et al., 21 Oct 2022, retrospective, Iraq, peer-reviewed, 1 author, study period June 2020 - September 2020.
Contact:
hayderc.allami@uokufa.edu.iq.
Abstract: DOI: 10.2478/cipms-2022-0020
Curr. Issues Pharm. Med. Sci., Vol. 35, No. 3, Pages 106-110
Current Issues in Pharmacy and Medical Sciences
Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA
journal homepage: http://www.curipms.umlub.pl/
Pharmacotherapy prescribing pattern and outcome
for hospitalized patients with severe and critical COVID-19
Hayder Assad
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kufa, Najaf, Iraq
ARTICLE INFO
Received 08 October 2021
Accepted 10 June 2022
Keywords:
COVID-19,
hospitalized patients,
medications,
mortality rate.
ABSTRACT
There are many treatment modalities for COVID-19 – with varied outcome. Therefore,
authors designed this study to assess prescribing patterns and the clinical outcome
for hospitalized patients with severe and critical COVID-19 so as to determine the most
effective approach.
Authors conducted a retrospective observational study on 346 adult patients with either
severe or critical COVID-19, who were admitted to public hospitals in Al-Najaf city, Iraq
from June to September 2020. Patients' information, medications and outcomes were
collected from their medical records in the registered office of the hospital.
A total of 346 patients were enrolled, with a majority of patients being adults above 35 years
old and male (70.2%). Most patients (81%) received corticosteroid as dexamethasone, and
about 45% of all patients were given convalescent plasma therapy, while a few patients
were prescribed antiviral favipiravir (23%) and lopinavir/ritonavir (19%). As supportive
care medications, anticoagulant such as enoxaparin was administered to most of the
patients (93%) and more than half of all patients received the broad-spectrum antibiotic,
meropenem.
The majority of the patients recovered and were discharged alive (66%), however, the inhospital mortality rate was 26%. Interestingly, patients treated with enoxaparin alone
or in combination with hydroxychloroquine were associated with better outcome.
The prescribing pattern of COVID-19 specific medications and supportive care is aligned
with guideline recommendations and associated with a beneficial therapeutic outcome.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit